[
    [
        {
            "time": "2018-03-15",
            "original_text": "Look at Abbott Laboratories’ Valuation Trend",
            "features": {
                "keywords": [
                    "valuation trend",
                    "Abbott Laboratories"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Look at Abbott Laboratories’ Valuation Trend",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "Analysts’ Most Recent Recommendations on ABT",
            "features": {
                "keywords": [
                    "analysts",
                    "recommendations",
                    "ABT"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Analysts’ Most Recent Recommendations on ABT",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-05-20",
            "original_text": "Abbott Laboratories Continues Its Bull Run with a Record High",
            "features": {
                "keywords": [
                    "bull run",
                    "record high",
                    "Abbott Laboratories"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Abbott Laboratories Continues Its Bull Run with a Record High",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-06-12",
            "original_text": "Abbott's Troponin-I Wins CE Mark, Vascular Arm Gets a Revamp",
            "features": {
                "keywords": [
                    "Troponin-I",
                    "CE Mark",
                    "vascular arm",
                    "revamp"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Abbott's Troponin-I Wins CE Mark, Vascular Arm Gets a Revamp",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-05",
            "original_text": "Abbott Labs' Test for Heart Attack Risk Granted With CE Mark",
            "features": {
                "keywords": [
                    "heart attack risk",
                    "CE Mark",
                    "Abbott Labs"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Abbott Labs' Test for Heart Attack Risk Granted With CE Mark",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-08-18",
            "original_text": "New Research Coverage Highlights CyberArk Software, Mercer International, American Airlines Group, Abbott Laboratories, Open Text, and The Kroger — Consolidated Revenues, Company Growth, and Expectations for 2018",
            "features": {
                "keywords": [
                    "research coverage",
                    "consolidated revenues",
                    "company growth",
                    "expectations",
                    "Abbott Laboratories"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "New Research Coverage Highlights CyberArk Software, Mercer International, American Airlines Group, Abbott Laboratories, Open Text, and The Kroger — Consolidated Revenues, Company Growth, and Expectations for 2018",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]